Optinose initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Optinose with a Buy rating and $5 price target. The analyst believes the near-term label extension catalyst for corticosteroid drugdevice combo nasal spray Xhance “defines a pivotal moment for the platform” with the supplemental new drug application FDA acton date of March 16. The says the label extension presents the opportunity to address the full range of chronic sinusitis or chronic rhinosinusitis patients.